



Health Insurance (Pathology Services Table) Amendment Regulations 2009 (No. 1)¹

Select Legislative Instrument 2009 No. 62

I, QUENTIN BRYCE, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the *Health Insurance Act 1973*.

Dated 9 April 2009

QUENTIN BRYCE
Governor-General

By Her Excellency's Command

NICOLA ROXON
Minister for Health and Ageing

1 Name of Regulations

These Regulations are the *Health Insurance (Pathology Services Table) Amendment Regulations 2009 (No. 1)*.

2 Commencement

These Regulations commence on 1 May 2009.

3 Amendment of *Health Insurance (Pathology Services Table) Regulations 2008*

Schedule 1 amends the *Health Insurance (Pathology Services Table) Regulations 2008*.

Schedule 1 Amendments

(regulation 3)

[1] Schedule 1, Part 2, paragraph 13 (7) (b)

substitute

(b) more than 1 of the services mentioned in items 73059, 73060, 73061, 73064 and 73065;

[2] Schedule 1, Part 2, paragraph 25 (4) (a)

after

66539,

insert

66607,

[3] Schedule 1, Part 2, subrule 25 (5)*after*

66551,

insert

66660,

[4] Schedule 1, Part 2, subrule 25 (5)*omit*

, 73314, 73315

[5] Schedule 1, Part 3, item 66605*substitute*

66605	Vitamins — quantitation of vitamins B1, B2, B3, B6 and C in blood, urine or other body fluid (Item is subject to rule 25)	31.15
-------	---	-------

[6] Schedule 1, Part 3, after item 66606*insert*

66607	Vitamins — quantitation of vitamins A and E in blood, urine or other body fluid (Item is subject to rule 25)	76.27
-------	--	-------

[7] Schedule 1, Part 3, item 66638*omit*

29.70

insert

49.70

[8] Schedule 1, Part 3, item 66659*omit*

in the equivocal range of the particular method of assay used to determine the level

insert

above the age-related median but below the age-related, method-specific 97.5% reference limit

[9] Schedule 1, Part 3, after item 66659*insert*

- | | | |
|-------|--|-------|
| 66660 | Prostate specific antigen (PSA), quantitation of 2 or more fractions of PSA and any derived index, including, if performed, a test described in item 66656, in the follow up of a PSA result that lies above the age-related, method-specific 97.5% reference limit, but below 10 µg/L | 37.80 |
| | (Item is subject to rule 25) | |

[10] Schedule 1, Part 3, after item 66832*insert*

- | | | |
|-------|--|-------|
| 66900 | Carbon-labelled urea breath test using oral C-13 or C-14 urea, including the measurement of exhaled ¹³ CO ₂ or ¹⁴ CO ₂ , (except if item 12533 applies) for: | 78.15 |
| | (a) the confirmation of <i>Helicobacter pylori</i> colonisation; or | |
| | (b) the monitoring of the success of eradication of <i>Helicobacter pylori</i> | |

[11] Schedule 1, Part 3, item 71200*omit*

kappa or

insert

kappa and

[12] Schedule 1, Part 3, item 73049*substitute*

73049 Cytology of material obtained directly from a patient by 68.60
fine needle aspiration of solid tissue, or tissues —
1 identified site

[13] Schedule 1, Part 3, item 73059*omit*

73049 and 73051

insert

73049, 73051 and 73062

[14] Schedule 1, Part 3, item 73060*omit*

73049

insert

73049, 73062

[15] Schedule 1, Part 3, item 73060*omit*

4 or more

insert

4 to 6

[16] Schedule 1, Part 3, item 73061*omit*

73049

insert

73049, 73062

[17] Schedule 1, Part 3, after item 73061*insert*

73062	Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues — 2 or more separately identified sites	89.60
73063	Cytology of material obtained directly from a patient by fine needle aspiration of solid tissue, or tissues, if an employee of an approved pathology authority also attends the aspiration for confirmation of sample adequacy	100.00
73064	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051 and 73062 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 7 to 10 antibodies (Item is subject to rule 13)	72.20
73065	Immunocytochemical examination of material obtained by procedures described in items 73045, 73047, 73049, 73051 and 73062 for the characterisation of a malignancy by immunofluorescence, immunoperoxidase or other labelled antibody techniques with multiple antigenic specificities per specimen — 11 or more antibodies (Item is subject to rule 13)	89.60

[18] Schedule 1, Part 3, item 73300*substitute*

73300	Detection of mutation of the FMR1 gene if: (a) the patient exhibits intellectual disability, ataxia, neurodegeneration, or premature ovarian failure consistent with an FMR1 mutation; or (b) the patient has a relative with an FMR1 mutation; 1 or more tests	103.10
-------	--	--------

[19] Schedule 1, Part 3, item 73314

omit

(Item is subject to rule 25)

[20] Schedule 1, Part 3, item 73315

omit

, 18A and 25

insert

and 18A

Note

1. All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the *Legislative Instruments Act 2003*. See <http://www.frli.gov.au>.